NASDAQ stock price data

Exact Sciences' ($EXAS) Stock Rises as FDA Approves Cologuard Plus, Setting New Benchmark in Colorectal Cancer Screening

Oct 4, 2024, 04:49 PM

Exact Sciences (NASDAQ: EXAS) announced that on Friday it received approval from the U.S. Food and Drug Administration (FDA) for its Cologuard Plus™ test, an improved stool-based screening assay for colorectal cancer. The Cologuard Plus test is a next-generation multitarget stool DNA test designed for non-invasive colorectal cancer screening in adults aged 45 and older who are at average risk for colorectal cancer (CRC). The FDA approval sets a new benchmark in non-invasive colorectal cancer screening, providing an improved option for early detection of colon cancer. Following the announcement, Exact Sciences' stock price rose.